Stocks · News reference

TuHURA Biosciences Submits Investigational New Drug Application With FDA For Trial Of Its TBS-2025 VISTA Antibody To Treat Molecularly Defined Subsets Of Acute Myeloid Leukemia

Jun 15, 2026, 11:52 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARAug 21, 2026, 9:00 PMSEC EDGAR
8-K filing — TuHURA Biosciences, Inc./NV (HURA)
Filed: 2026-08-21 AccNo: 0001193125-26-361272 Size: 168 KB Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits
Read original at edgar
HURA
BenzingaAug 18, 2026, 12:19 PMBenzinga Newsdesk
Citizens Reiterates Market Outperform on TuHURA Biosciences, Maintains $9 Price Target
Citizens analyst Silvan Turkcan reiterates TuHURA Biosciences (NASDAQ:HURA) with a Market Outperform and maintains $9 price target.
Read original at benzinga
HURA
BenzingaAug 14, 2026, 12:04 PMBenzinga Newsdesk
TuHURA Biosciences Q2 EPS $(0.14) Beats $(0.15) Estimate
TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 33.33 percent increase over losses of $(0.21) per share
Read original at benzinga
HURA